MedTrace Logo

Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System

NCT01543295 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-07-29

No results posted yet for this study

Summary

This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® Syphilis Screen and Confirm rapid test. The device is intended to qualitatively and simultaneously detect the presence of antibodies to Non-treponemal and Treponema pallidum antigens in whole blood (capillary and venous), serum or plasma.

Conditions

  • Syphilis

Sponsors & Collaborators

  • Chembio Diagnostic Systems, Inc.

    lead INDUSTRY

Principal Investigators

  • Neil T Constantine, Ph.D · University of Maryland, Baltimore

  • Anthony LaMarca, M.D. · Therafirst Medical Center

  • Neva Yeganeh, M.D. · University of California, Los Angeles, David Geffen School of Medicine

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543295 on ClinicalTrials.gov